Summary
Semaglutide is associated with a high prevalence of adverse events, and its long-term safety is unknown. In an observational study, semaglutide was associated with a more than fourfold and sevenfold risk of nonarteritic anterior ischemic optic neuropathy in people taking semaglutide for type 2 diabetes and weight loss, respectively.
Source: SciTechDaily
Exclusive AI-Powered News Insights (For Members only)
Disclaimer:This content is AI-generated from various trusted sources and is intended for informational purposes only. While we strive for accuracy, we encourage you to verify details independently. Use the contact button to share feedback on any inaccuracies—your input helps us improve!
